Neurocognitive Risks in Children With Solid Tumors
Recruiting now
Conditions studied: Solid Tumor in Children
In brief
The survival rate of children with cancer has improved significantly in recent years thanks to the progress of different therapies. The neurocognitive sequelae related to treatments and illness are more or less well known. Four factors seem to be associated with neurocognitive sequelae: treatment, the tumor itself, environmental factors like the socio-economic status of parents and biological factors. Main purpose of the study is to establish a score to assess the risk of neurocognitive sequelae in these children based on these factors (treatment, tumor, and environmental factors)
Key facts
- Study ID
- NCT03609112
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
- People needed
- 1000
- Starts
- 2014-10-01
- Expected to finish
- 2025-09-01
- Last updated by the study team
- 2024-12-13
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient aged 6 to 16 years and 11 months during the study period
- Type of pathology: solid tumor
- Place of treatment and follow-up: Gustave Roussy
- Minimum time from the end of the initial treatment:
- For patients who have not received treatment with methotrexate: 6 months
- For patients being treated with methotrexate: none
- Obtaining the non-opposition of parents / legal representatives
- Affiliation to a social security scheme.
You may not qualify if…
- Patients with other pathologies associated with mental retardation (autism, genetic syndrome ...)
- Patients lost to follow-up
- Deceased patients
- Patients treated for a pathology whose prognosis is involved in the very short term (infiltrating glioma of the brainstem, recurrence of the pathology during treatment)
- Non-French speaking patients
Where it is running
- Gustave Roussy — Villejuif, Val De Marne, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.